Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Sedrak MS, Sun CL, Ji J, Cohen HJ, Gross CP, Tew WP, Klepin HD, Wildes TM, Dotan E, Freedman RA, O'Connor T, Chow S, Fenton MA, Moy B, Chapman AE, Dale W, Katheria V, Kuderer NM, Lyman GH, Magnuson A, Muss HB. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. J Clin Oncol. 2023 Jan 10; 41(2):316-326.
-
Nakhlis F, Portnow L, Gombos E, Daylan AEC, Leone JP, Kantor O, Richardson ET, Ho A, Dunn SA, Ohri N. Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy. Curr Probl Surg. 2022 09; 59(9):101191.
-
Cobain EF, Hayes DF. Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022 11 10; 40(32):3673-3676.
-
Vasudevan SA, Meyers RL, Finegold MJ, L?pez-Terrada D, Ranganathan S, Dunn SP, Langham MR, McGahren ED, Tiao GM, Weldon CB, Malogolowkin MH, Krailo MD, Piao J, Randazzo J, Towbin AJ, BethMcCarville M, O'Neill AF, Furman WL, Rodriguez-Galindo C, Katzenstein HM. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731. J Pediatr Surg. 2022 Oct; 57(10):251-256.
-
O'Cearbhaill RE, P?rez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, D?rum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, Gonz?lez-Mart?n A. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022 07; 166(1):36-43.
-
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clin Cancer Res. 2022 May 02; 28(9):1871-1880.
-
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 12 16; 385(25):2336-2347.
-
Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 02; 26(2):376-386.
-
Williams AD, Ciocca R, Sabol JL, Carp NZ. Institutions Treating Breast Cancer Patients of a Low Socioeconomic Status Achieve Multidisciplinary Quality Standards at Lower Rates. Ann Surg Oncol. 2021 Oct; 28(10):5635-5647.
-
Fear VS, Forbes CA, Neeve SA, Fisher SA, Chee J, Waithman J, Ma SK, Lake R, Nowak AK, Creaney J, Brown MD, Saunders C, Robinson BWS. Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer Immunol Immunother. 2021 Nov; 70(11):3249-3258.